clinical trial · NCT06411314
Efficacy and Safety of Natamycin and Lactulose Vaginal Suppositories in Treatment of Vulvovaginal Candidiasis
Avva Rus, JSC·phase3·completed·n = 218
Vulvovaginal Candidiasis, GenitalNatamycin + Lactulose 100 mg + 300 mg vaginal suppositoriesLactulose 300 mg vaginal suppositoriesPimafucin® (natamycin) 100 mg vaginal suppositories
brief summary
The purpose is to study superior efficacy of combination of Natamycin and Lactulose (Natamycin 100 mg + Lactulose 300 mg vaginal suppositories) compared to Pimafucin (Natamycin 100 mg vaginal suppositories), or Lactulose 300 mg vaginal suppositories. The second objective of the study was to investigate the safety of the combination suppositories in the treatment of vulvovaginal candidiasis in non-pregnant adult females.
started
Dec 29, 2022
primary completion
Jul 26, 2023
completion
Sep 22, 2023
last updated
May 13, 2024
official title
Efficacy and Safety of Vaginal Suppositories Containing Combination of Natamycin and Lactulose in Treatment of Vulvovaginal Candidiasis: International, Randomized, Controlled, Superiority Clinical Trial
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol